U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Paraparesis

MedGen UID:
113150
Concept ID:
C0221166
Sign or Symptom
Synonym: Parapareses
SNOMED CT: Paraparesis (1845001)
 
HPO: HP:0002385

Definition

Weakness or partial paralysis in the lower limbs. [from HPO]

Conditions with this feature

Adrenoleukodystrophy
MedGen UID:
57667
Concept ID:
C0162309
Disease or Syndrome
X-linked adrenoleukodystrophy (X-ALD) affects the nervous system white matter and the adrenal cortex. Three main phenotypes are seen in affected males: The childhood cerebral form manifests most commonly between ages four and eight years. It initially resembles attention-deficit disorder or hyperactivity; progressive impairment of cognition, behavior, vision, hearing, and motor function follow the initial symptoms and often lead to total disability within six months to two years. Most individuals have impaired adrenocortical function at the time that neurologic disturbances are first noted. Adrenomyeloneuropathy (AMN) manifests most commonly in an individual in his twenties or middle age as progressive stiffness and weakness of the legs, sphincter disturbances, sexual dysfunction, and often, impaired adrenocortical function; all symptoms are progressive over decades. "Addison disease only" presents with primary adrenocortical insufficiency between age two years and adulthood and most commonly by age 7.5 years, without evidence of neurologic abnormality; however, some degree of neurologic disability (most commonly AMN) usually develops by middle age. More than 20% of female carriers develop mild-to-moderate spastic paraparesis in middle age or later. Adrenal function is usually normal.
Charcot-Marie-Tooth disease X-linked dominant 1
MedGen UID:
98290
Concept ID:
C0393808
Disease or Syndrome
GJB1 disorders are typically characterized by peripheral motor and sensory neuropathy with or without fixed CNS abnormalities and/or acute, self-limited episodes of transient neurologic dysfunction (especially weakness and dysarthria). Peripheral neuropathy typically manifests in affected males between ages five and 25 years. Although both men and women are affected, manifestations tend to be less severe in women, some of whom may remain asymptomatic. Less commonly, initial manifestations in some affected individuals are stroke-like episodes (acute fulminant episodes of reversible CNS dysfunction).
Deficiency of guanidinoacetate methyltransferase
MedGen UID:
154356
Concept ID:
C0574080
Disease or Syndrome
The creatine deficiency disorders (CDDs), inborn errors of creatine metabolism and transport, comprise three disorders: the creatine biosynthesis disorders guanidinoacetate methyltransferase (GAMT) deficiency and L-arginine:glycine amidinotransferase (AGAT) deficiency; and creatine transporter (CRTR) deficiency. Developmental delay and cognitive dysfunction or intellectual disability and speech-language disorder are common to all three CDDs. Onset of clinical manifestations of GAMT deficiency (reported in ~130 individuals) is between ages three months and two years; in addition to developmental delays, the majority of individuals have epilepsy and develop a behavior disorder (e.g., hyperactivity, autism, or self-injurious behavior), and about 30% have movement disorder. AGAT deficiency has been reported in 16 individuals; none have had epilepsy or movement disorders. Clinical findings of CRTR deficiency in affected males (reported in ~130 individuals) in addition to developmental delays include epilepsy (variable seizure types and may be intractable) and behavior disorders (e.g., attention deficit and/or hyperactivity, autistic features, impulsivity, social anxiety), hypotonia, and (less commonly) a movement disorder. Poor weight gain with constipation and prolonged QTc on EKG have been reported. While mild-to-moderate intellectual disability is commonly observed up to age four years, the majority of adult males with CRTR deficiency have been reported to have severe intellectual disability. Females heterozygous for CRTR deficiency are typically either asymptomatic or have mild intellectual disability, although a more severe phenotype resembling the male phenotype has been reported.
Oculodentodigital dysplasia
MedGen UID:
167236
Concept ID:
C0812437
Congenital Abnormality
Oculodentodigital syndrome is characterized by a typical facial appearance and variable involvement of the eyes, dentition, and fingers. Characteristic facial features include a narrow, pinched nose with hypoplastic alae nasi, prominent columella and thin anteverted nares together with a narrow nasal bridge, and prominent epicanthic folds giving the impression of hypertelorism. The teeth are usually small and carious. Typical eye findings include microphthalmia and microcornea. The characteristic digital malformation is complete syndactyly of the fourth and fifth fingers (syndactyly type III) but the third finger may be involved and associated camptodactyly is a common finding (summary by Judisch et al., 1979). Neurologic abnormalities are sometimes associated (Gutmann et al., 1991), and lymphedema has been reported in some patients with ODDD (Brice et al., 2013). See review by De Bock et al. (2013). Genetic Heterogeneity of Oculodentodigital Syndrome An autosomal recessive form of ODDD (257850) is also caused by mutation in the GJA1 gene, but the majority of cases are autosomal dominant.
Neurofibromatosis, familial spinal
MedGen UID:
320296
Concept ID:
C1834235
Disease or Syndrome
Spinal neurofibromatosis is an autosomal dominant disorder characterized by a high load of spinal tumors. These tumors may be asymptomatic or result in neurologic symptoms, including back pain, difficulty walking, and paresthesias. Spinal NF is considered to be a subtype of neurofibromatosis type I (NF1; 162200), which is an allelic disorder. Patients with spinal NF may or may not have the classic cutaneous cafe-au-lait pigmentary macules or ocular Lisch nodules typically observed in patients with classic NF1. Patients with spinal NF should be followed closely for spinal sequelae (summary by Burkitt Wright et al., 2013).
Biotin-responsive basal ganglia disease
MedGen UID:
375289
Concept ID:
C1843807
Disease or Syndrome
Biotin-thiamine-responsive basal ganglia disease (BTBGD) may present in childhood, early infancy, or adulthood. The classic presentation of BTBGD occurs in childhood (age 3-10 years) and is characterized by recurrent subacute encephalopathy manifest as confusion, seizures, ataxia, dystonia, supranuclear facial palsy, external ophthalmoplegia, and/or dysphagia which, if left untreated, can eventually lead to coma and even death. Dystonia and cogwheel rigidity are nearly always present; hyperreflexia, ankle clonus, and Babinski responses are common. Hemiparesis or quadriparesis may be seen. Episodes are often triggered by febrile illness or mild trauma or stress. Simple partial or generalized seizures are easily controlled with anti-seizure medication. An early-infantile Leigh-like syndrome / atypical infantile spasms presentation occurs in the first three months of life with poor feeding, vomiting, acute encephalopathy, and severe lactic acidosis. An adult-onset Wernicke-like encephalopathy presentation is characterized by acute onset of status epilepticus, ataxia, nystagmus, diplopia, and ophthalmoplegia in the second decade of life. Prompt administration of biotin and thiamine early in the disease course results in partial or complete improvement within days in the childhood and adult presentations, but most with the infantile presentation have had poor outcome even after supplementation with biotin and thiamine.
Charcot-Marie-Tooth disease X-linked recessive 3
MedGen UID:
375530
Concept ID:
C1844865
Disease or Syndrome
A rare genetic peripheral sensorimotor neuropathy with an X-linked recessive inheritance pattern and the childhood to adolescent-onset of progressive, distal muscle weakness and atrophy (beginning in the lower extremities and then affecting the upper extremities), as well as distal, pan sensory loss in the upper and lower extremities, pes cavus, and absent or reduced distal tendon reflexes. Pain and paraesthesia are frequently the initial sensory symptoms. Spastic paraparesis (manifested by clasp-knife sign, hyperactive deep-tendon reflexes, and Babinski sign) has also been reported.
Kufor-Rakeb syndrome
MedGen UID:
338281
Concept ID:
C1847640
Disease or Syndrome
Kufor-Rakeb syndrome is a rare autosomal recessive form of juvenile-onset atypical Parkinson disease (PARK9) associated with supranuclear gaze palsy, spasticity, and dementia. Some patients have neuroradiologic evidence of iron deposition in the basal ganglia, indicating that the pathogenesis of PARK9 can be considered among the syndromes of neurodegeneration with brain iron accumulation (NBIA; see 234200) (summary by Bruggemann et al., 2010). For a phenotypic description and a discussion of genetic heterogeneity of Parkinson disease (PD), see 168600. Biallelic mutation in the ATP13A2 gene also causes autosomal recessive spastic paraplegia-78 (SPG78; 617225), an adult-onset neurodegenerative disorder with overlapping features. Patients with SPG78 have later onset and prominent spasticity, but rarely parkinsonism. Loss of ATP13A2 function results in a multidimensional spectrum of neurologic features reflecting various regions of the brain and nervous system, including cortical, pyramidal, extrapyramidal, brainstem, cerebellar, and peripheral (summary by Estrada-Cuzcano et al., 2017).
Mitochondrial complex III deficiency nuclear type 2
MedGen UID:
767519
Concept ID:
C3554605
Disease or Syndrome
Mitochondrial complex III deficiency nuclear type 2 is an autosomal recessive severe neurodegenerative disorder that usually presents in childhood, but may show later onset, even in adulthood. Affected individuals have motor disability, with ataxia, apraxia, dystonia, and dysarthria, associated with necrotic lesions throughout the brain. Most patients also have cognitive impairment and axonal neuropathy and become severely disabled later in life (summary by Ghezzi et al., 2011). The disorder may present clinically as spinocerebellar ataxia or Leigh syndrome, or with psychiatric disturbances (Morino et al., 2014; Atwal, 2014; Nogueira et al., 2013). For a discussion of genetic heterogeneity of mitochondrial complex III deficiency, see MC3DN1 (124000).
Frontotemporal dementia and/or amyotrophic lateral sclerosis 1
MedGen UID:
854771
Concept ID:
C3888102
Disease or Syndrome
C9orf72 frontotemporal dementia and/or amyotrophic lateral sclerosis (C9orf72-FTD/ALS) is characterized most often by frontotemporal dementia (FTD) and upper and lower motor neuron disease (MND); however, atypical presentations also occur. Age at onset is usually between 50 and 64 years (range: 20-91 years) irrespective of the presenting manifestations, which may be pure FTD, pure amyotrophic lateral sclerosis (ALS), or a combination of the two phenotypes. The clinical presentation is highly heterogeneous and may differ between and within families, causing an unpredictable pattern and age of onset of clinical manifestations. The presence of MND correlates with an earlier age of onset and a worse overall prognosis.
Paget disease of bone 2, early-onset
MedGen UID:
899166
Concept ID:
C4085251
Disease or Syndrome
Paget disease is a metabolic bone disease characterized by focal abnormalities of increased bone turnover affecting one or more sites throughout the skeleton, primarily the axial skeleton. Bone lesions in this disorder show evidence of increased osteoclastic bone resorption and disorganized bone structure. See reviews by Ralston et al. (2008) and Ralston and Albagha (2014). For a discussion of genetic heterogeneity of Paget disease of bone, see 167250.
Intellectual disability, autosomal dominant 56
MedGen UID:
1638835
Concept ID:
C4693389
Mental or Behavioral Dysfunction
Mitochondrial complex V (ATP synthase) deficiency, nuclear type 4A
MedGen UID:
1841116
Concept ID:
C5830480
Disease or Syndrome
Mitochondrial complex V deficiency nuclear type 4A (MC5DN4A) is an autosomal dominant metabolic disorder characterized by poor feeding and failure to thrive in early infancy. Laboratory studies show increased serum lactate, alanine, and ammonia, suggesting mitochondrial dysfunction. Some affected individuals show spontaneous resolution of these symptoms in early childhood and have subsequent normal growth and development, whereas others show developmental delay with impaired intellectual development and movement abnormalities, including dystonia, ataxia, or spasticity; these neurologic deficits are persistent (Lines et al., 2021, Zech et al., 2022). For a discussion of genetic heterogeneity of mitochondrial complex V deficiency, nuclear types, see MC5DN1 (604273).

Professional guidelines

PubMed

Soltani A, Hashemy SI, Zahedi Avval F, Soleimani A, Rafatpanah H, Rezaee SA, Griffith R, Mashkani B
Biomed Pharmacother 2019 Jan;109:770-778. Epub 2018 Nov 5 doi: 10.1016/j.biopha.2018.10.139. PMID: 30551530
Vissarionov SV, Krutelev NA, Snischuk VP, Alam M, Kravchenko AP, Zheng YP, Khusainov NO
Spinal Cord Ser Cases 2018;4:109. Epub 2018 Dec 19 doi: 10.1038/s41394-018-0141-0. PMID: 30588335Free PMC Article
Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K, Pache F, Stich O, Beume LA, Hümmert MW, Ringelstein M, Trebst C, Winkelmann A, Schwarz A, Buttmann M, Zimmermann H, Kuchling J, Franciotta D, Capobianco M, Siebert E, Lukas C, Korporal-Kuhnke M, Haas J, Fechner K, Brandt AU, Schanda K, Aktas O, Paul F, Reindl M, Wildemann B; in cooperation with the Neuromyelitis Optica Study Group (NEMOS)
J Neuroinflammation 2016 Sep 27;13(1):280. doi: 10.1186/s12974-016-0718-0. PMID: 27793206Free PMC Article

Recent clinical studies

Etiology

Clauze A, Enose-Akahata Y, Jacobson S
Front Immunol 2022;13:984274. Epub 2022 Sep 15 doi: 10.3389/fimmu.2022.984274. PMID: 36189294Free PMC Article
Lallemant-Dudek P, Durr A
Rev Neurol (Paris) 2021 May;177(5):550-556. Epub 2020 Aug 15 doi: 10.1016/j.neurol.2020.07.001. PMID: 32807405
van den Berg B, Fokke C, Drenthen J, van Doorn PA, Jacobs BC
Neurology 2014 Jun 3;82(22):1984-9. Epub 2014 May 7 doi: 10.1212/WNL.0000000000000481. PMID: 24808021
Thompson TP, Pearce J, Chang G, Madamba J
Spine (Phila Pa 1976) 2004 Aug 15;29(16):E353-6. doi: 10.1097/01.brs.0000134689.84162.e7. PMID: 15303045
Bangham CR
J Clin Pathol 2000 Aug;53(8):581-6. doi: 10.1136/jcp.53.8.581. PMID: 11002759Free PMC Article

Diagnosis

Román GC
Handb Clin Neurol 2023;196:149-156. doi: 10.1016/B978-0-323-98817-9.00026-0. PMID: 37620067
King-Robson J, Hampton T, Rosadas C, Taylor GP, Stanton B
Pract Neurol 2022 Feb;22(1):60-63. Epub 2021 Aug 30 doi: 10.1136/practneurol-2021-003053. PMID: 34462338
Zhovtis Ryerson L, Herbert J, Howard J, Kister I
J Neurol Sci 2014 Nov 15;346(1-2):43-50. Epub 2014 Sep 19 doi: 10.1016/j.jns.2014.09.015. PMID: 25263600
van den Berg B, Fokke C, Drenthen J, van Doorn PA, Jacobs BC
Neurology 2014 Jun 3;82(22):1984-9. Epub 2014 May 7 doi: 10.1212/WNL.0000000000000481. PMID: 24808021
Román GC
Handb Clin Neurol 2014;121:1521-48. doi: 10.1016/B978-0-7020-4088-7.00102-4. PMID: 24365434

Therapy

Goyal V, Elavarasi A, Kumar A, Samal P, Garg A, Shukla G, Vishnu VY, Singh MB, Srivastava MVP
Indian J Tuberc 2022 Jul;69(3):325-333. Epub 2021 May 29 doi: 10.1016/j.ijtb.2021.05.002. PMID: 35760482
Lallemant-Dudek P, Durr A
Rev Neurol (Paris) 2021 May;177(5):550-556. Epub 2020 Aug 15 doi: 10.1016/j.neurol.2020.07.001. PMID: 32807405
Misra S, Ramesh R, Ramu ChS, Srirangalaxmi G, Radhakrishn H, Vajresware
J Assoc Physicians India 2012 Jul;60:58-61. PMID: 23405547
Nienaber CA, Rousseau H, Eggebrecht H, Kische S, Fattori R, Rehders TC, Kundt G, Scheinert D, Czerny M, Kleinfeldt T, Zipfel B, Labrousse L, Ince H; INSTEAD Trial
Circulation 2009 Dec 22;120(25):2519-28. Epub 2009 Dec 7 doi: 10.1161/CIRCULATIONAHA.109.886408. PMID: 19996018
Strom T, Schneck SA
Neurology 1991 Feb;41(2 ( Pt 1)):325-6. doi: 10.1212/wnl.41.2_part_1.325. PMID: 1812840

Prognosis

Khan MI, Garg RK, Rizvi I, Malhotra HS, Kumar N, Jain A, Verma R, Sharma PK, Pandey S, Uniyal R, Jain P
Neurol Sci 2022 Sep;43(9):5615-5624. Epub 2022 Jun 23 doi: 10.1007/s10072-022-06221-6. PMID: 35739331Free PMC Article
Riad H, Knafo S, Segnarbieux F, Lonjon N
Neurochirurgie 2013 Feb;59(1):30-4. Epub 2013 Feb 8 doi: 10.1016/j.neuchi.2012.10.137. PMID: 23395186
Gessain A, Mahieux R
Rev Neurol (Paris) 2012 Mar;168(3):257-69. Epub 2012 Mar 7 doi: 10.1016/j.neurol.2011.12.006. PMID: 22405461
Nienaber CA, Rousseau H, Eggebrecht H, Kische S, Fattori R, Rehders TC, Kundt G, Scheinert D, Czerny M, Kleinfeldt T, Zipfel B, Labrousse L, Ince H; INSTEAD Trial
Circulation 2009 Dec 22;120(25):2519-28. Epub 2009 Dec 7 doi: 10.1161/CIRCULATIONAHA.109.886408. PMID: 19996018
Takatsuki K
Intern Med 1995 Oct;34(10):947-52. doi: 10.2169/internalmedicine.34.947. PMID: 8563094

Clinical prediction guides

Dias ÁRN, Falcão LFM, Quaresma JAS
Front Immunol 2022;13:914498. Epub 2022 Jul 1 doi: 10.3389/fimmu.2022.914498. PMID: 35844492Free PMC Article
Ramezani S, Rezaee SA, Farjami Z, Ebrahimi N, Abdullabass HK, Ibrahim Jebur MI, Rafatpanah H, Akbarin MM
Microb Pathog 2022 Aug;169:105622. Epub 2022 Jun 7 doi: 10.1016/j.micpath.2022.105622. PMID: 35688412
Takenouchi N, Tanaka M, Sato T, Yao J, Fujisawa JI, Izumo S, Kubota R, Matsuura E
J Neurovirol 2020 Jun;26(3):404-414. Epub 2020 Apr 13 doi: 10.1007/s13365-020-00838-z. PMID: 32285300
Nardone R, Höller Y, Storti M, Lochner P, Tezzon F, Golaszewski S, Brigo F, Trinka E
World J Gastroenterol 2014 Mar 14;20(10):2578-85. doi: 10.3748/wjg.v20.i10.2578. PMID: 24627593Free PMC Article
Gessain A, Mahieux R
Rev Neurol (Paris) 2012 Mar;168(3):257-69. Epub 2012 Mar 7 doi: 10.1016/j.neurol.2011.12.006. PMID: 22405461

Recent systematic reviews

Sultan S, Concannon J, Veerasingam D, Tawfick W, McHugh P, Jordan F, Hynes N
Cochrane Database Syst Rev 2022 Apr 1;4(4):CD012926. doi: 10.1002/14651858.CD012926.pub2. PMID: 35363887Free PMC Article
Moulakakis KG, Karaolanis G, Antonopoulos CN, Kakisis J, Klonaris C, Preventza O, Coselli JS, Geroulakos G
J Vasc Surg 2018 Aug;68(2):634-645.e12. doi: 10.1016/j.jvs.2018.03.410. PMID: 30037680
de Beer MH, Eysink Smeets MM, Koppen H
Neurologist 2017 Jan;22(1):34-39. doi: 10.1097/NRL.0000000000000100. PMID: 28009771
Goodwin CR, Abu-Bonsrah N, Boone C, Ruiz-Valls A, Sankey EW, Sarabia-Estrada R, Elder BD, Kosztowski T, Sciubba DM
J Clin Neurosci 2016 May;27:22-7. Epub 2016 Jan 8 doi: 10.1016/j.jocn.2015.11.003. PMID: 26778049
Clardy SL, Lennon VA, Dalmau J, Pittock SJ, Jones HR Jr, Renaud DL, Harper CM Jr, Matsumoto JY, McKeon A
JAMA Neurol 2013 Dec;70(12):1531-6. doi: 10.1001/jamaneurol.2013.4442. PMID: 24100349Free PMC Article

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Consumer resources

    Recent activity

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...